SCHEMBL5453519

SCHEMBL5453519

Cc1ccc(SCc2cc(C(=O)NO)no2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
HDAC6 Q9UBN7 8/20 0.45
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
HTT P42858 1/20 0.43
HDAC1 Q13547 5/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451531 0.86 MEN1 (0.56) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5448449 0.86 THRB (0.48) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL14582444 0.86 ALDH1A1 (0.48) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5461144 0.85 MEN1 (0.54) MEN1KMT2ANPC1RAB9ALMNA
SCHEMBL5458978 0.83 PPARD (0.51) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5458329 0.82 LMNA (0.44) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5460232 0.82 HDAC6 (0.59) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5454441 0.79 HDAC6 (0.46) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5446344 0.78 L3MBTL1 (0.60) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL5456148 0.78 ALDH1A1 (0.53) MEN1KMT2ANPC1RAB9AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US claimed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP claimed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO claimed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP disclosed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors PDF, MRPL21, PEPD MEN1 1390/4885KMT2A 3828/4885NPC1 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.